Freya Biosciences, a trans-Atlantic biotech company specializing in women’s health, announces positive topline results from its first Phase 1 clinical study of its lead asset FB101, an investigational vaginal microbial immunotherapeutic. These data allow the company to expand the clinical activities with FB101 to women seeking infertility treatment and undergoing in vitro fertilization (IVF).